Loading…
Simple
Expanded
Grid
By Venue
The Westin Boston Seaport District clear filter
arrow_back View All Dates
Tuesday, October 1
 

7:45am EDT

Registration Open and Networking Breakfast
Tuesday October 1, 2024 7:45am - 8:45am EDT
The Westin Boston Seaport District
Tuesday October 1, 2024 7:45am - 8:45am EDT
The Westin Boston Seaport District
  Networking

8:45am EDT

Welcome and Day 2 Opening Remarks
Tuesday October 1, 2024 8:45am - 9:00am EDT
The Westin Boston Seaport District
Speakers
avatar for Michelle Benz

Michelle Benz

Conference Production Director, Fierce Life Sciences
Michelle Benz joined Questex, Fierce Life Sciences in 2021 as a senior conference producer and works on several events annually including Fierce Biotech Summit, Fierce Leaders in Life Sciences, Fierce Pharma PR & Communications Summits East and West, Fierce Pharma Meeting Professionals... Read More →
Tuesday October 1, 2024 8:45am - 9:00am EDT
The Westin Boston Seaport District
  Main Stage

9:00am EDT

Keynote: Reimagining Medicine, Together: Partnering to Advance Patient Care
Tuesday October 1, 2024 9:00am - 9:30am EDT
The Westin Boston Seaport District
As the biotech industry continues to deliver cutting-edge innovations, pharma companies like Novartis are partnering to share expertise, scale these discoveries and accelerate their path to market, all in service of the patient. In light of ever-increasing competition and costs, more collaboration and partnerships are needed in order to bring these new medicines to the patients who need them. Pharma companies and biotech need to join forces to ensure that the most promising innovations have the best chance of reaching patients. Hear how Novartis has adopted a ‘deal type agnostic’ approach which has led to successful collaborations and partnerships that maximize mutual value and focus on improving patient care.

Interviewed by: Michelle Benz, Fierce
Speakers
avatar for Reshema Kemps-Polanco

Reshema Kemps-Polanco

Executive Vice President and Chief Commercial Officer, Novartis
Reshema Kemps-Polanco is Executive Vice President and Chief Commercial Officer of Novartis US, the U.S. operations of global biopharmaceutical company, Novartis AG. In this role, she is responsible for the end-to-end commercialization across four therapeutic areas, including oncology... Read More →
avatar for Michelle Benz

Michelle Benz

Conference Production Director, Fierce Life Sciences
Michelle Benz joined Questex, Fierce Life Sciences in 2021 as a senior conference producer and works on several events annually including Fierce Biotech Summit, Fierce Leaders in Life Sciences, Fierce Pharma PR & Communications Summits East and West, Fierce Pharma Meeting Professionals... Read More →
Tuesday October 1, 2024 9:00am - 9:30am EDT
The Westin Boston Seaport District
  Main Stage

9:30am EDT

Plan to Win: Why it’s never too early to make the key Regulatory, Strategic, and Market Decisions that will Define your Trajectory
Tuesday October 1, 2024 9:30am - 10:15am EDT
The Westin Boston Seaport District
Moderators
avatar for Alice Valder Curran

Alice Valder Curran

Partner, Hogan Lovells
Alice Valder Curran advises pharmaceutical manufacturers regarding drug pricing matters, with a particular emphasis on the Medicaid Drug Rebate Program, the Medicare average sales price (ASP) reporting requirement, the Health Resources and Services Administration (HRSA) 340B Drug... Read More →
Speakers
avatar for Casarine Chong (Cassie)

Casarine Chong (Cassie)

Senior VP | Deputy GC Transactions, Bristol Myers Squibb
Casarine (Cassie) Chong is Senior Vice President, Deputy General Counsel, Transactions for Bristol Myers Squibb. Cassie and her organization provide strategic and business-enabling support of all significant transactions, including mergers & acquisitions, venture investments and strategic... Read More →
avatar for Tess Cameron

Tess Cameron

Principal, RA Capital Management
Tess Cameron is a Principal on the Investment Team at RA Capital Management. Tess works on both public and private investments and serves on several company boards. Previously, Tess held finance leadership roles at Foghorn Therapeutics, Wave Life Sciences, and Biogen. Prior to joining... Read More →
Tuesday October 1, 2024 9:30am - 10:15am EDT
The Westin Boston Seaport District
  Main Stage

10:15am EDT

Panel: Unlocking Health Equity: AI-Driven Innovations in Diverse Clinical Trial Recruitment
Tuesday October 1, 2024 10:15am - 11:00am EDT
The Westin Boston Seaport District
Join us for an impactful panel discussion on leveraging AI-driven innovations to address the critical challenge of health equity in clinical trial recruitment. Rapid advances in AI are revolutionizing healthcare delivery, showing remarkable potential in diagnosing a range of clinical conditions. However, to truly advance patient care and ensure equitable access to healthcare services, stakeholders in the clinical research ecosystem must unite to support the development of an inclusive infrastructure.
  • Delve into how AI can revolutionize patient recruitment by identifying investigators and patients in underrepresented communities, promoting diversity and inclusivity in trials.
  • Examine case studies and best practices in leveraging AI to overcome barriers to diversity in research participation.
  • Assess the ethical and regulatory imperatives of prioritizing health equity in trial recruitment efforts.
Moderators
avatar for Adrelia Allen, Pharm.D.

Adrelia Allen, Pharm.D.

Executive Director, Clinical Trial Diversity, Merck Research Laboratories
Adrelia Allen is Executive Director of Clinical Trial Patient Diversity in Merck Research Laboratories.  Adrelia brings more than 25 years of experience in clinical research and clinical operations execution across multiple therapeutic areas.  She joined Merck as a Sales Representative... Read More →
Speakers
avatar for Shaheen Lakhan, MD, PhD, FAAN

Shaheen Lakhan, MD, PhD, FAAN

Chief Medical Officer, Click Therapeutics
Shaheen Lakhan is the Chief Medical Officer (CMO) at Click Therapeutics. He is a physician-scientist, biotech executive, and biopharma board director with more than 20 years of experience in healthcare, academia, and industry focusing on neuroscience research and development. Dr... Read More →
avatar for Stacey Bledsoe, RN, MSN

Stacey Bledsoe, RN, MSN

Head of Global Clinical Trial Diversity and Inclusion, Gilead Sciences, Inc
Stacey Bledsoe, RN, MSN joined Gilead Sciences in July 2023 as the new Head of Global Clinical Trial Diversity and Inclusion. Stacey will be responsible for leading the effort to increase the diversity of Gilead’s clinical trials across the portfolio while bolstering Gilead’s... Read More →
avatar for Meghan McKenzie, M.A.

Meghan McKenzie, M.A.

Principal, Patient Inclusion and Health Equity, Genentech
Meghan McKenzie works in Patient Inclusion and Health Equity in Genentech’s Chief Diversity Office. She develops strategies to drive greater inclusion of racial and ethnically representative patient populations in clinical research and to advance health equityGaining patient, clinician... Read More →
Tuesday October 1, 2024 10:15am - 11:00am EDT
The Westin Boston Seaport District
  Main Stage

11:00am EDT

Networking Break
Tuesday October 1, 2024 11:00am - 11:30am EDT
The Westin Boston Seaport District
Tuesday October 1, 2024 11:00am - 11:30am EDT
The Westin Boston Seaport District
  Networking

11:30am EDT

Day 2: Tracks Begin
Tuesday October 1, 2024 11:30am - 11:30am EDT
The Westin Boston Seaport District
Strategy & Dealmaking Track Chair:

PR & Communications Track Chair: Kristin Cahill, Global CEO, GCI Health

Preclinical & CMC Track Chair:

Early-Stage Development Track Chair: Dr. Karim I. Budhwani, CEO, CerFlux
Speakers
avatar for Dr. Karim I. Budhwani

Dr. Karim I. Budhwani

CEO, CerFlux
For more than two decades Dr. Budhwani has combined his passion for innovation, socioeconomic development, and scientific discoveries to shape the impact of innovation and new knowledge (INK) in advancing the economy and the broader human society. He co-founded CerFlux, Inc. in 2018... Read More →
avatar for Kristin Cahill

Kristin Cahill

Global CEO, GCI Group
Kristin Cahill is the Global Chief Executive Officer of GCI Health. Throughout her 20-year career, Kristin has worked with a wide range of healthcare organizations and executives to develop innovative strategies, compelling communication platforms and breakthrough creative campaigns... Read More →
Tuesday October 1, 2024 11:30am - 11:30am EDT
The Westin Boston Seaport District

11:30am EDT

Empowering Women's Health: Impact of President Biden's Executive Order on Biotech Innovation and Research
Tuesday October 1, 2024 11:30am - 12:00pm EDT
The Westin Boston Seaport District
This case study presentation will delve into the executive order that President Biden issued on March 18th, 2024 and how it impacts the biotech community with early-stage drug research and development. We will discuss what this means, how to move forward, and what might change as a result of this long overdue order and focus. Explore how this order will facilitate easier access to resources and funding, making women's health initiatives more accessible and impactful. Gain insights into the evolving strategies of researchers and scientists in response to this new focus, and discuss the long-term implications for drug development, research, and funding in women's health.
Speakers
avatar for Cheryl Rucker-Whitaker, MD, MPH, FACP

Cheryl Rucker-Whitaker, MD, MPH, FACP

Regional President, CINQCARE
Dr. Rucker-Whitaker is physician executive with CINQCARE, a health and care company focused on caring for people where they live. She is an active entrepreneur, advisor, and board member. She co-founded a company focused on patient engagement for the hard to reach. She is an advisor... Read More →
avatar for Charlotte Owens, MD, FACOG

Charlotte Owens, MD, FACOG

Head of Medical Affairs and Outcomes Research, Organon
Charlotte is responsible for the global medical strategy and support of marketed and pipeline products, including outcomes research. Additionally, she develops and fosters relationships with external organizations and experts to ensure that our products continue to meet market needs... Read More →
Tuesday October 1, 2024 11:30am - 12:00pm EDT
The Westin Boston Seaport District
  Track: Early-Stage Development

11:30am EDT

Dynamic Duos: Navigating Challenges and Building Success in the CEO-Comms Partnership
Tuesday October 1, 2024 11:30am - 12:00pm EDT
The Westin Boston Seaport District
What does it take for a successful CEO / Head of Communications relationship to work? What are the biggest external and internal challenges these two leaders face in the current environment and how do they navigate them together? This fireside chat will answer these questions and will open it up to answer yours!​​​​
Speakers
avatar for Sarah Spencer

Sarah Spencer

Vice President, Corporate Communications & Investor Relations, Vor Bio
Sarah Spencer is a Corporate Communications professional with over 25 years of experience in the pharmaceutical, life sciences, and biotechnology industries. She currently serves as Vice President of Corporate Communications & Investor Relations at Vor Bio. Sarah's expertise includes... Read More →
avatar for Robert Ang, MBBS, MBA

Robert Ang, MBBS, MBA

President and CEO, Vor Bio
Robert Ang, MBBS, MBA, is President and CEO at Vor Bio since 2019. Prior to Vor Bio, Robert gained operational experience focused on strategy and business development through roles at Neon Therapeutics (now BioNTech), Bavarian Nordic, and Cadence Pharmaceuticals (now Mallinckrodt... Read More →
Tuesday October 1, 2024 11:30am - 12:00pm EDT
The Westin Boston Seaport District
  Track: PR & Communications
  • QTAG pr&commsfeaturedsessions

11:30am EDT

Fierce Fireside Chat with James Wilson M.D., Ph.D.
Tuesday October 1, 2024 11:30am - 12:00pm EDT
The Westin Boston Seaport District
Moderated by: Darren Incorvaia, Staff Writer, Fierce Biotech

Speaker: James Wilson M.D., Ph.D., CEO of GEMMA Biotherapeutics and Franklin Biolabs
Speakers
avatar for James M. Wilson, MD, PhD

James M. Wilson, MD, PhD

CEO of GEMMABio, Chairman of Franklin Biolabs and
Having started his work in gene therapy nearly 40 years ago, Dr. Wilson was recruited to the University of Pennsylvania in 1993 and created the first and largest academic-based program in gene therapy. His laboratory discovered a family of viruses from primates called adeno-associated... Read More →
avatar for Darren Incorvaia

Darren Incorvaia

Staff Writer, Fierce Biotech
Darren Incorvaia is a staff writer for Fierce Biotech. He joined Fierce in 2024 and has also written for The New York Times, Science, and Science News, among others. He was an early-career fellow at The Open Notebook in 2023 and has a Ph.D. in Ecology, Evolution and Behavior from... Read More →
Tuesday October 1, 2024 11:30am - 12:00pm EDT
The Westin Boston Seaport District
  Track: Preclinical & CMC

11:30am EDT

Lessons Learned From a Billion Dollar Deal
Tuesday October 1, 2024 11:30am - 12:00pm EDT
The Westin Boston Seaport District
  • Dive into a candid conversation between two top dealmakers as they share the strategies and key decisions that drove the success of their recent high-profile deals.
  • Discover how these leaders approached complex partnerships, the lessons they took away from their deals, and how they leveraged innovative thinking to navigate challenges and secure sustainable outcomes.
  • Hear insights into their motivations, the strategic goals behind their negotiations, and the crucial factors that contributed to their successes.
Speakers
avatar for Albert Hsia

Albert Hsia

Executive Director, Business Development, Merck & Co.
Albert Hsia leads Oncology and Immunology business development at Merck’s Boston Hub, focusing on innovative opportunities for partnership and M&A that can accelerate the development of breakthrough medicines for the most challenging diseases.Albert came to Merck with broad business... Read More →
avatar for Polly Brown

Polly Brown

Head of Business Development, Oncology R&D, AstraZeneca
Polly leads Oncology business development activities, including search and evaluation, transactions and alliance management. She also leads the development and execution of a fully integrated Oncology R&D BD strategy. Within this role, Polly has overseen the in-licensing of multiple... Read More →
Tuesday October 1, 2024 11:30am - 12:00pm EDT
The Westin Boston Seaport District
  Track: Strategy & Dealmaking
  • QTAG stratanddealmakingfeaturedsessions

12:00pm EDT

Panel: Pioneering Early-Stage Cancer Therapies: Harnessing Therapeutic Cancer Vaccines for Precision Medicine
Tuesday October 1, 2024 12:00pm - 12:45pm EDT
The Westin Boston Seaport District
This session dives into the transformative potential of therapeutic cancer vaccines in early-stage drug development within the biotech industry. Recent breakthroughs, including an mRNA cancer vaccine's success against glioblastoma, highlight a promising avenue for creating targeted and personalized therapies. Discover how this innovative technology can be harnessed to create personalized therapies, advance precision medicine, and revolutionize patient care. Explore the strategic integration of therapeutic cancer vaccines into drug development pipelines, and gain valuable insights into refining protocols, identifying candidate selection, and navigating regulatory pathways.

Panel Closed
Moderators
avatar for Jonathan Kagan Ph.D.

Jonathan Kagan Ph.D.

Co-founder and President of Corner Therapeutics, Marian R. Neutra, PhD Professor of Pediatrics at Harvard Medical School, and the Director of Basic Research and Shwachman Chair in Gastroenterology at Boston Children’s Hospital
Jonathan Kagan is a cofounder, President and board director of Corner Therapeutics, the immunotherapy company unlocking lifelong protection from cancer and infectious diseases.Outside of Corner, he is Marian R. Neutra, Ph.D. Professor of Pediatrics at Harvard Medical School and the director of Basic Research and Shwachman Chair in Gastroenterology at Boston Child... Read More →
Speakers
avatar for Matthew Hawryluk, Ph.D.

Matthew Hawryluk, Ph.D.

EVP & Chief Business Officer, Gritstone bio, Inc.
Matthew Hawryluk, Ph.D. has served as our Executive Vice President and Chief Business Officer since October 2015. Prior to Gritstone, from April 2011 to October 2015, Dr. Hawryluk held positions of increasing responsibility at Foundation Medicine, a public molecular diagnostics company... Read More →
avatar for Jeff Allen, PhD

Jeff Allen, PhD

President & CEO, Friends of Cancer Research
Jeff Allen, Ph.D. serves as the President and CEO of Friends of Cancer Research (Friends). For over 25 years, Friends has created unique scientific partnerships, accelerated policy change, and supported groundbreaking research to deliver new therapies to patients quickly and safely... Read More →
avatar for Dr. Ildiko Csiki

Dr. Ildiko Csiki

Chief Medical Officer, Geneos Therapeutics
Dr. Csiki is the Chief Medical Officer at Geneos Therapeutics, focusing on development of personalized therapeutic cancer vaccines. With over 20 years in oncology, she has driven innovation in cancer research, drug development, and immunotherapy. She has held execututive leadership... Read More →
avatar for Scot W. Ebbinghaus M.D.

Scot W. Ebbinghaus M.D.

Vice President and Therapeutic Area Head Oncology Late Stage Development, Merck Research Laboratories
Dr. Scot Ebbinghaus joined Merck Research Labs Late Stage Oncology Development in 2007. He is currently Vice President and Therapeutic Area Head for Late Stage Oncology Development.Dr. Ebbinghaus has played key roles in the development of the lead indication for KEYTRUDA® in melanoma... Read More →
Tuesday October 1, 2024 12:00pm - 12:45pm EDT
The Westin Boston Seaport District
  Track: Early-Stage Development

12:00pm EDT

Panel: Parallel Paths, Different Landscapes: Unveiling the Nuances of Pharma vs. Biotech Communications
Tuesday October 1, 2024 12:00pm - 12:45pm EDT
The Westin Boston Seaport District
Join us for an enlightening panel session featuring experienced communicators from both the biotech and pharma sectors as they delve into the unique challenges and opportunities of transitioning between industries. The panel will explore the nuances of communication expectations, priorities, and stakeholders in biotech versus pharma, shedding light on the shifts required when navigating these parallel paths.
  • Understand the key differences and similarities between biotech and pharma communicators, fostering a deeper appreciation for cross-industry communication strategies and partnerships.
  • Address the growing trend of pharma communicators transitioning to biotech and the potential challenges they may face in understanding the nuances of biotech communications.
  • Discover effective strategies for building partnerships between biotech and pharma, navigating expectations, and preparing teams for successful M&A transitions.
Moderators
avatar for Caitlin Craparo

Caitlin Craparo

Senior Director, US Communications, Genmab
Caitlin Craparo is Senior Director, US Communications at Genmab, a global biotechnology company. In this role, Caitlin is responsible for executing strategic communications that support the company’s growth in the US.With more than 15 years of experience leading communications for... Read More →
Speakers
avatar for Aron Feingold

Aron Feingold

Vice President, Investor Relations & Corporate Communications, Geron Corporation
Aron Feingold has more than 15 years of experience in biotech and pharmaceutical strategic communications. She is currently the VP of Investor Relations and Corporate Communications at Geron, a commercial-stage biopharmaceutical company aiming to change lives by changing the course... Read More →
avatar for Ed Harnaga

Ed Harnaga

Chief Communications Officer, Pfizer
Ed is responsible for all external communications activities across Pfizer including corporate reputation, branding, media relations, digital and social media, executive positioning, with a focus on supporting Pfizer’s Commercial, Research and Development and Manufacturing organizations... Read More →
avatar for Courtney Walker

Courtney Walker

Chief Growth Officer, MMC & RXMOSAIC
As the leader of RXMOSAIC and Chief Growth Officer of sister-agency MMC, Walker works hand-in-glove with the healthcare industry’s most consequential people and brands, including Merck, Pfizer, Regeneron/Sanofi, AstraZeneca, Novartis, Amgen, and an array transformational mid-cap... Read More →
avatar for Sarah Alspach

Sarah Alspach

SVP, External Affairs, bluebird bio
Tuesday October 1, 2024 12:00pm - 12:45pm EDT
The Westin Boston Seaport District
  Track: PR & Communications
  • QTAG pr&commsfeaturedsessions

12:00pm EDT

Panel: Streamlining Efficiency: Addressing the Complexity of the Cell Therapy Supply Chain for Clinical to Commercial Advancement of Transformative Therapies
Tuesday October 1, 2024 12:00pm - 12:45pm EDT
The Westin Boston Seaport District
For decades, pharmaceutical firms have relied on batch manufacturing, a method prone to inefficiencies and long hold times, and moved towards continuous manufacturing to reduce cycle times. As the cell therapy space increasingly moves away from small batches and looks to increase throughput and scale, we are now asking ourselves how we can also make the cell therapy supply chain a “continuous process” to address complexities and advance as an industry. This session explores the need for end-to-end solutions for cell therapy products including cGMP manufacturing supply chain considerations across the entire product lifecycle to enhance efficiency and cost-effectiveness and improve process consistency. Discover how cell therapy companies can achieve reductions in operating costs, waste, and cycle times while enhancing product quality to respond to market demands for these transformative therapies.
Moderators
avatar for Michael Paglia, M.S.

Michael Paglia, M.S.

Chief Technology Officer, ElevateBio BaseCamp
Michael has spent the last twenty years in biotechnology building, leading and motivating process development and manufacturing teams to support clinical programs from early development to late-stage clinical trials. Currently, Michael is the Chief Technology Officer at ElevateBio... Read More →
Speakers
avatar for Nabiha Saklayen, Ph.D.

Nabiha Saklayen, Ph.D.

CEO & Co-Founder, Cellino
Nabiha Saklayen is CEO and co-founder of Cellino, where her team is spearheading the biomanufacturing of regenerative medicines to make “Your Cells, Your Cure” a reality for patients in an aging and increasingly diverse world. As a purpose-driven physicist, she focused her Ph.D... Read More →
avatar for Shishir Gadam, PHD

Shishir Gadam, PHD

Chief Technical Officer, CARGO Therapeutics
Dr. Shishir Gadam joined CARGO Therapeutics as CTO in January 2022. He is a seasoned biotechnology leader with over 25 years of experience and brings a wealth of CMC experience across vaccines, biologics and cell therapy modalities. Shishir is passionate about building strong technical... Read More →
avatar for Kate Rochlin, Ph.D.

Kate Rochlin, Ph.D.

Chief Operating Officer, IN8bio
Kate Rochlin, Ph.D., is Chief Operating Officer at IN8bio (NASDAQ: INAB). She previously served as the VP and AVP of Operations and Innovation since August 2020. She has over 15 years of extensive expertise in early-stage biotechnology and company development, including conducting... Read More →
avatar for Tim Kelly

Tim Kelly

Chief Technology Officer, Caribou Bio
Tim Kelly is a biotech executive with over 20 years of leadership experience, currently serving as Chief Technology Officer at Caribou Biosciences. Previously, he was CEO of OXB Solutions LLC, where he led the spin-out of a new cell and gene therapy business. He also served as COO... Read More →
Tuesday October 1, 2024 12:00pm - 12:45pm EDT
The Westin Boston Seaport District
  Track: Preclinical & CMC

12:00pm EDT

Panel: Strategic Insights: Navigating Biotech M&A and Dealmaking Landscape in 2024 and Beyond
Tuesday October 1, 2024 12:00pm - 12:45pm EDT
The Westin Boston Seaport District
This panel is designed to provide strategic insights and actionable intelligence for navigating the evolving landscape of biotech M&A and dealmaking in 2024 and beyond.
  • Examine the latest trends shaping biotech M&A activities, including deal sizes, strategic motivations, and market dynamics.
  • Discuss the impact of recent M&A transactions on the industry landscape and competitive positioning.
  • Predict and discuss strategic insights for dealmakers, including potential deal structures, sector-specific opportunities, and regulatory considerations for 2025 and beyond.
  • Evaluate the impact of M&A and dealmaking activities on biotech innovation, R&D pipelines, and industry growth.
Moderators
avatar for Naomi Fried, PhD

Naomi Fried, PhD

CEO, PharmStars
Naomi Fried is CEO of PharmStars, the pharma-focused accelerator for digital health startups. She was Biogen’s VP of Innovation; Boston Children’s Hospital’s first Chief Innovation Officer; and Kaiser’s VP of Innovation & Advanced Technology.
Speakers
avatar for Maha Radhakrishnan, MD

Maha Radhakrishnan, MD

Executive Partner, Private Equity, Sofinnova Investments
Maha Radhakrishnan, M.D is currently Executive Partner at Sofinnova Investments and in her most recent role was Consultant to the CEO at Dyne Therapeutics helping with the overarching strategy and direction to the company R&D and Commercialization efforts. Prior to that she was the... Read More →
avatar for Fred Chereau

Fred Chereau

SVP, Strategy & Business Development, Alexion, AstraZeneca Rare Disease
Fred brings close to 30 years of biotech, pharmaceutical, and medical device experience to Alexion, where he oversees strategy and business development activities. Prior to joining Alexion, he served as president and chief executive officer of LogicBio. Previously, Fred served as... Read More →
avatar for Jennifer Woo

Jennifer Woo

Senior Director Strategy and Business Development, Sanofi
Jennifer Woo is a Senior Director of Strategy and Business Development at Sanofi, where she leads strategy development and BD initiatives to drive growth and innovation. With over 17 years of experience in strategy, corporate development, and portfolio and program management, Jennifer... Read More →
avatar for Luba Greenwood, JD

Luba Greenwood, JD

Managing Partner, Binney Street Capital Venture Fund, Dana-Farber Cancer Institute
Luba Greenwood is a distinguished executive, investor, and company builder with over 20 years of experience in the healthcare and tech sectors. Luba has served as the Chief Executive Officer and Chair of the Board of Kojin Therapeutics, a leader in ferroptosis. She currently serves... Read More →
Tuesday October 1, 2024 12:00pm - 12:45pm EDT
The Westin Boston Seaport District
  Track: Strategy & Dealmaking
  • QTAG stratanddealmakingfeaturedsessions

12:45pm EDT

Networking Lunch
Tuesday October 1, 2024 12:45pm - 1:45pm EDT
The Westin Boston Seaport District
Tuesday October 1, 2024 12:45pm - 1:45pm EDT
The Westin Boston Seaport District
  Networking

1:45pm EDT

BioPharmaGPT: A VC’s Perspective on Fluff vs Substance in AI-Enabled Drug Discovery
Tuesday October 1, 2024 1:45pm - 2:15pm EDT
The Westin Boston Seaport District
ChatGPT’s success put into motion an arms race across physical world industries to build vertical-specific foundation models, with biotech emerging as its own battleground. AI has the power to change the biotech landscape as we know it, but the industry stands at a unique intersection of opportunity and complexity, which will ultimately determine the winners and the failures. Ben Hemani, Founding Partner of Bison Ventures, will dive into why most attempts to build biology foundation models are destined to fall short and how biotechs can emerge as true AI leaders, offering a roadmap for the future leaders of biotech innovation.
Speakers
avatar for Ben Hemani

Ben Hemani

Founding Partner, Bison Ventures
Ben is an engineer-turned-investor who is passionate about guiding frontier technology businesses towards massive commercial success and impact in collaboration with equally driven entrepreneurs. While a generalist at heart, Ben particularly loves businesses that utilize AI to enable... Read More →
Tuesday October 1, 2024 1:45pm - 2:15pm EDT
The Westin Boston Seaport District
  Main Stage

2:15pm EDT

Panel: A Revival in Neuro Therapeutics
Tuesday October 1, 2024 2:15pm - 3:00pm EDT
The Westin Boston Seaport District
The past year witnessed a substantial influx of investment into the neuroscience sector, culminating in several high-value deals during the fourth quarter of 2023. The trend continues into this year, with several companies aiming to delve deeper into neuroscience and psychiatric disease. What lies ahead? Join this panel discussion as experts examine emerging trends, breakthroughs, and disease targets within the neuropharmaceutical field, providing valuable insights into the future direction of research and development in this area.
 
Moderated by: Fraiser Kansteiner, Staff Writer, Fierce Pharma
Panel Closed
Moderators
avatar for Fraiser Kansteiner

Fraiser Kansteiner

Staff Writer, Fierce Pharma
Fraiser Kansteiner is a staff writer at Fierce Pharma. He joined the Fierce team in 2020 and covers topics such as manufacturing, COVID-19 and drug delivery. He also manages Fierce Biotech and Fierce Pharma’s LinkedIn showcase pages. Before diving into pharma reporting, Fraiser... Read More →
Speakers
avatar for Camille L. Bedrosian, M.D.

Camille L. Bedrosian, M.D.

Chief Medical Officer, Amylyx
Dr. Bedrosian joined Amylyx as Chief Medical Officer (CMO) in 2023, bringing to the company nearly 30 years of experience in building successful clinical development and translation research programs in the pharmaceutical industry. Dr. Bedrosian served most of her nearly six years... Read More →
avatar for Craig Thompson

Craig Thompson

CEO, Cerevance
Craig Thompson, CEO of Cerevance, brings over 25 years of commercial and marketing leadership experience in the biotech and pharmaceutical industries. Prior to joining Cerevance, he was the president and CEO of Neurana Pharmaceuticals, a private company focused on the treatment of... Read More →
avatar for Sara Kenkare-Mitra, Ph.D.

Sara Kenkare-Mitra, Ph.D.

President and Head of Research and Development, Alector
Dr. Sara Kenkare-Mitra, Ph.D., is a seasoned biotech/pharma drug developer, scientist and executive, currently serving as the President and Head of Research and Development at Alector since 2021. With over 25 years of industry experience, she has dedicated her career to developing... Read More →
avatar for Blake Mandell

Blake Mandell

Co-founder and CEO, Transcend Therapeutics
Blake Mandell is the co-founder and CEO of Transcend Therapeutics, a clinical-stage, neuroscience-focused company developing rapid-acting treatments for neuropsychiatric diseases. Transcend's mission is to develop new drugs for the millions of people for whom current psychiatric medicines have not worked. Blake was named to Forbes' "30 under 30" and has lectured at University of Pennsylvania and Brown University... Read More →
Tuesday October 1, 2024 2:15pm - 3:00pm EDT
The Westin Boston Seaport District
  Main Stage

3:00pm EDT

Closing Remarks
Tuesday October 1, 2024 3:00pm - 3:15pm EDT
The Westin Boston Seaport District
Speakers
avatar for Michelle Benz

Michelle Benz

Conference Production Director, Fierce Life Sciences
Michelle Benz joined Questex, Fierce Life Sciences in 2021 as a senior conference producer and works on several events annually including Fierce Biotech Summit, Fierce Leaders in Life Sciences, Fierce Pharma PR & Communications Summits East and West, Fierce Pharma Meeting Professionals... Read More →
Tuesday October 1, 2024 3:00pm - 3:15pm EDT
The Westin Boston Seaport District
  Main Stage

3:15pm EDT

Close of Conference
Tuesday October 1, 2024 3:15pm - 3:15pm EDT
The Westin Boston Seaport District
Tuesday October 1, 2024 3:15pm - 3:15pm EDT
The Westin Boston Seaport District
 
Share Modal

Share this link via

Or copy link

Filter sessions
Apply filters to sessions.
Filtered by Date - 
Clear filter
Monday, September 30
Tuesday, October 1
The Westin Boston Seaport District
  • Main Stage
  • Networking
  • Track: Early-Stage Development
  • Track: PR & Communications
  • Track: Preclinical & CMC
  • Track: Strategy & Dealmaking